Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02132845 · ClinicalTrials.gov registry record · NA
Next Generation Sequence Target-Directed Therapy in Treating Patients With Cancer
A NA study, sponsored by Fox Chase Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 30
- Enrollment target
NCT02132845 is a NA study that has completed, run by Fox Chase Cancer Center. The registered enrollment target is 30 participants.
The verdict
NCT02132845, a NA study, has completed, sponsored by Fox Chase Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
Study Summary
This randomized clinical trial studies how well next generation sequence target-directed therapy works in treating patients with cancer. Next generation sequencing is a test that screens for mutations to cancer related genes. Target-directed therapy is a type of treatment that uses drugs or other substances to identify and attack specific types of cancer cells that may have less harm to normal cells. Next generation sequencing may help identify these specific types of cancer cells.
Interventions
- OTHER laboratory biomarker analysis
- OTHER cytology specimen collection procedure
- DRUG targeted therapy
- PROCEDURE therapeutic procedure
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2016-03-17 |
| Est. Completion | 2018-05-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02132845
The ClinicalTrials.gov registry entry for NCT02132845 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fox Chase Cancer Center, which has 183 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which laboratory biomarker analysis is the first listed.
NCT02132845 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02132845 about?
NCT02132845 is a clinical study titled "Next Generation Sequence Target-Directed Therapy in Treating Patients With Cancer". This randomized clinical trial studies how well next generation sequence target-directed therapy works in treating patients with cancer. Next generation sequencing is a test that screens for mutations to cancer related genes. Target-directed therapy is a type of treatment that uses drugs or other su...
What is the current status of trial NCT02132845?
This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2016-03-17. Estimated completion is 2018-05-10.
What interventions are being tested in trial NCT02132845?
The interventions under investigation include: laboratory biomarker analysis (OTHER), cytology specimen collection procedure (OTHER), targeted therapy (DRUG), therapeutic procedure (PROCEDURE).
Who is sponsoring clinical trial NCT02132845?
This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.